Illustration of the tumur microenvironment in triple-negative breast
Download scientific diagram | Illustration of the tumur microenvironment in triple-negative breast cancer. Notes: Data from Zhou Y, Tian Q, Wang BY, Yang J, Zhao SD, Yang J. The prognostic significance of TILs as a biomarker in triple-negative breast cancer: what is the role of TILs in TME of TNBC? Adapted from Zhou Y, Tian Q, Wang BY, Yang J, Zhao SD, Yang J. The prognostic significance of TILs as a biomarker in triple-negative breast cancer: what is the role of TILs in TME of TNBC. Eur Rev Med Pharmacol Sci. 2021;25(7):2885-2897. Creative Commons. 7 from publication: Advances in Tumour-Infiltrating Lymphocytes for Triple-Negative Breast Cancer Management | Triple negative breast cancer (TNBC) is a subtype of breast cancer which does not express or expresses a minimum amount of estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor 2 (HER2) protein. TNBCs include a heterogenic group of | Breast Cancer Management, Triple Negative Breast Neoplasms and Tumor-Infiltrating Lymphocytes | ResearchGate, the professional network for scientists.
Remodeling the tumor microenvironment for improved CAR T-cell therapy
Frontiers Immune Lymphocyte Infiltrate and its Prognostic Value in Triple-Negative Breast Cancer
2. Tumor spatial autocorrelation and clinical prognosis • BIRSBIO2020.scProteomics.exploratory
Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance - ScienceDirect
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects. - Abstract - Europe PMC
Get an Overview of Tumor Microenvironment- CUSABIO
A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging: Cell
IJMS, Free Full-Text
Frontiers Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer
Initial Results from Phase 2 Mechanism of Action Trial in
Schematic illustration of pH activation of nanoparticle by tumor